Impala Nordic comments on OncoZenge AB (publ) ("OncoZenge" or the "Company") Q1 2026 and the receipt of full European regulatory approval to initiate the pivotal Phase III trial of BupiZenge™.
The CTA approval is one of the most important milestones in the Company's history, removes the primary near-term uncertainty, and triggers committed financing from both Yangtian Pharma and Molteni Farmaceutici amounting to approximately 21 MSEK. The spotlight now shifts decisively to first patient enrollment, recruitment pace, and ultimately trial readout.